Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Q 122 (Primary)
  • Indications Hot flashes
  • Focus Proof of concept; Therapeutic Use
  • Sponsors QUE Oncology

    • Most Recent Events

    • 05 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 19 Oct 2018 Planned End Date changed from 1 Jul 2019 to 1 Aug 2019.
    • 19 Oct 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top